Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jared Weiss

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS MetastasesMarcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Head & Neck|June 5, 2013
Clinical significance of indeterminate pulmonary nodules in patients with locally advanced head and neck squamous cell carcinomaRaphael E Alford, David V Fried, Benjamin Y Huang, et al.
Journal for Immunotherapy of Cancer|December 6, 2019
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumorsEzra E W Cohen, Michael J Pishvaian, Dale R Shepard, et al.
Head & Neck|August 30, 2020
Decline in circulating viral and human tumor markers after resection of head and neck carcinomaErin M Lopez, April Michelle Tanner, Eugenie Du, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 6, 2016
Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck CancerAaron D Falchook, Rebecca Green, Mary E Knowles, et al.
International Journal of Radiation Oncology, Biology, Physics|November 20, 2015
Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell CarcinomaBhishamjit S Chera, Robert J Amdur, Joel Tepper, et al.
Cancer|March 27, 2018
Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinomaBhishamjit S Chera, Robert J Amdur, Joel E Tepper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor MutationsHelena A Yu, Alexander Spira, Leora Horn, et al.
JAMA Oncology|August 9, 2019
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical TrialThomas E Stinchcombe, Pasi A Jänne, Xiaofei Wang, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinomaTanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS MetastasesMarcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Head & Neck|June 5, 2013
Clinical significance of indeterminate pulmonary nodules in patients with locally advanced head and neck squamous cell carcinomaRaphael E Alford, David V Fried, Benjamin Y Huang, et al.
Journal for Immunotherapy of Cancer|December 6, 2019
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumorsEzra E W Cohen, Michael J Pishvaian, Dale R Shepard, et al.
Head & Neck|August 30, 2020
Decline in circulating viral and human tumor markers after resection of head and neck carcinomaErin M Lopez, April Michelle Tanner, Eugenie Du, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 6, 2016
Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck CancerAaron D Falchook, Rebecca Green, Mary E Knowles, et al.
International Journal of Radiation Oncology, Biology, Physics|November 20, 2015
Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell CarcinomaBhishamjit S Chera, Robert J Amdur, Joel Tepper, et al.
Cancer|March 27, 2018
Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinomaBhishamjit S Chera, Robert J Amdur, Joel E Tepper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2017
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor MutationsHelena A Yu, Alexander Spira, Leora Horn, et al.
JAMA Oncology|August 9, 2019
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical TrialThomas E Stinchcombe, Pasi A Jänne, Xiaofei Wang, et al.
Cancer Immunology, Immunotherapy : CII|March 2, 2024
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinomaTanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, et al.
Pageof 10